Nuvasive's three product lines to drive 2022 revenue growth- Needham

NuVasive

24/03/2022 12:16

** Nuvasive's three product lines can drive majority of the
company's 2022 revenue growth of about 5%-8%, Needham analysts
say 
    ** Believe NUVA's robotics system used for spine surgeries,
Pulse, its cervical disc replacement device Simplify Disc, and
NuVasive Specialized Orthopedics unit to collectively contribute
about 490 basis points to 2022 rev growth 
    ** Brokerage estimates NUVA's International unit alone could
add 100 basis points to revenue growth in 2022 
    ** Says NUVA's other areas of strength include surgical and
implant products such as X360, Modulus, COHERE, C360 - which can
aid NUVA towards a "beat and raise" 2022 
    ** Other growth catalysts include NUVA's Pulse robotic arm,
which has first-in-human procedure expected this year
    ** 8 of 17 brokerages rate the stock "buy" or higher, 7 rate
it  "hold" and 2 rate it "sell"; their median PT is $60,
pointing to ~18% upside to Wednesday's close 
    ** NUVA fell 6.8% in 2021 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))